Premium
Prognostic value of MMP‐2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma
Author(s) -
Väisänen Anne,
Kallioinen Matti,
Taskinen Pentti J.,
TurpeenniemiHujanen Taina
Publication year - 1998
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/(sici)1096-9896(199809)186:1<51::aid-path131>3.0.co;2-p
Subject(s) - melanoma , immunostaining , medicine , pathology , immunoperoxidase , basement membrane , collagenase , staining , immunohistochemistry , atypia , biopsy , antibody , biology , monoclonal antibody , immunology , cancer research , enzyme , biochemistry
Abstract The penetration of the subepithelial basement membrane is the first critical step in the dissemination of melanoma. In vitro studies have suggested that the 72 kD type IV collagenase (MMP‐2) may be important in melanoma invasion. It has recently been demonstrated that the expression of MMP‐2 immunoreactive protein increased with increasing atypia in melanocytic tumours and was associated with later haematogenous metastases in melanoma. This paper investigates the value of MMP‐2 as a possible prognostic marker in melanoma. The expression of MMP‐2 immunoreactive protein was studied with immunoperoxidase staining in paraffin‐embedded sections of 50 cases of primary skin melanoma by using specific, affinity purified antibodies. Positive immunostaining was quantified by counting the percentage of positive cancer cells and was compared with clinical patient characteristics and survival. Sixty‐four per cent of the primary melanoma cases displayed positive cytoplasmic immunostaining for MMP‐2 in tumour cells. Marked overexpression of MMP‐2 protein (≥34 per cent of melanoma cells positive) correlated with the 5‐year survival of the patients when compared with patients with lower MMP‐2 positivity, 55 per cent vs. 85 per cent, respectively ( P< 0·05). Male patients displayed positive staining more often than females (75 per cent vs. 54 per cent, respectively). There was no correlation between MMP‐2 positivity and Clark level or Breslow classification. A distinct group with unfavourable prognosis was identified. The 10‐year survival for MMP‐2‐positive male melanoma patients was 39 per cent as opposed to 79 per cent with the other melanoma patients ( P< 0·05). In the hierarchic Cox regression model for survival, MMP‐2 immunoreactive protein was found to be independent of Clark level and Breslow classification. Overexpression of MMP‐2 protein indicated a 4·5‐fold relative risk of dying from melanoma. It is concluded that MMP‐2 immunoreactive protein in melanoma cells is an independent prognostic factor for survival. High MMP‐2 expression in male melanoma patients indicates an unfavourable prognosis. © 1998 John Wiley & Sons, Ltd.